Guillermo Bosch

Guillermo Bosch

Auto-generated profile, based on publicly available information

Guillermo Bosch

Department of Epidemiology and Evaluation,IMIM (Hospital del Mar Medical Research Institute)

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
GBGuillermo Bosch
Guillermo Bosch
MCMercè Comas
Mercè Comas
LDLaia Domingo
Laia Domingo
AGAnna Guillen‐Sola
Anna Guillen‐Sola
EDEsther Duarte
Esther Duarte
MSMaria Sala
Maria Sala

10 June 2022 in eLife
Verified
Journal Article
Open access
GBGuillermo Bosch
Guillermo Bosch
MPMargarita Posso
Margarita Posso
JLJavier Louro
Javier Louro
MRMarta Roman
Marta Roman
MPMiquel Porta
Miquel Porta
FMFrancesc Macià
Francesc Macià
Background: To assess the effect of the COVID-19 pandemic on performance indicators in the population-based breast cancer screening program of Parc de Salut Mar (PSMAR), Barcelona, Spain.Methods: We conducted a before-and-after, study to evaluate participation, recall, false positives, the cancer detection rate, and cancer characteristics in our screening population from March 2020 to March 2021 compared with the four previous rounds (2012–2019). Using multilevel logistic regression models, we estimated the adjusted odds ratios (aORs) of each of the performance indicators for the COVID-19 period, controlling by type of screening (prevalent or incident), socioeconomic index, family history of breast cancer, and menopausal status. We analyzed 144,779 invitations from 47,571women.Results: During the COVID-19 period, the odds of participation were lower in first-time invitees (aOR = 0.90 [95% CI = 0.84–0.96]) and in those who had previously participated regularly and irregularly (aOR = 0.63 [95% CI = 0.59–0.67] and aOR = 0.95 [95% CI = 0.86–1.05], respectively). Participation showed a modest increase in women not attending any of the previous rounds (aOR = 1.10 [95% CI = 1.01–1.20]). The recall rate decreased in both prevalent and incident screening (aOR = 0.74 [95% CI = 0.56–0.99] and aOR = 0.80 [95% CI = 0.68–0.95], respectively). False positives also decreased in both groups (prevalent aOR = 0.92 [95% CI = 0.66–1.28] and incident aOR = 0.72 [95% CI = 0.59–0.88]). No significant differences were observed in compliance with recall (OR = 1.26, 95% CI = 0.76–2.23), cancer detection rate (aOR = 0.91 [95% CI = 0.69–1.18]), or cancer stages.Conclusions: The COVID-19 pandemic negatively affected screening attendance, especially in previous participants and newcomers. We found a reduction in recall and false positives and no marked differences in cancer detection, indicating the robustness of the program. There is a need for further evaluations of interval cancers and potential diagnostic delays.Funding: This study has received funding by grants PI19/00007 and PI21/00058, funded by Instituto de Salud Carlos III (ISCIII) and cofunded by the European Union and Grant RD21/0016/0020 funded by Instituto de Salud Carlos III and by the European Union NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MRR).

1 January 2025 in European Journal of Cancer Care
Verified
Journal Article
Open access
VZVíctor Zamora
Víctor Zamora
GBGuillermo Bosch
Guillermo Bosch
VBVirginia Becerra
Virginia Becerra
OGOlatz Garin
Olatz Garin
MÁMónica Ávila
Mónica Ávila
MFMontserrat Ferrer
Montserrat Ferrer
Objectives: To perform a cost‐effectiveness analysis based on primary data from a cohort of patients with localized prostate cancer followed throughout 10 years, comparing radical prostatectomy, brachytherapy, and external beam radiotherapy (EBRT) and applying disease‐specific utilities, from a national health system’s perspective. Materials and Methods: Patients diagnosed with localized prostate cancer were consecutively recruited in 2003–2005 from 10 Spanish hospitals ( n = 674) (ClinicalTrials.gov number: NCT01492751). The expanded prostate cancer index composite (EPIC) and short‐form 36 (SF‐36) questionnaires were administered through telephone interviews before treatment and annually during follow‐up. The outcome measures to evaluate the incremental cost‐effectiveness ratio between treatments (ICER) were quality‐adjusted life‐years (QALYs), calculated by the patient‐oriented prostate utility scale (PORPUS) utility index, obtained with a mapping from the EPIC and the SF‐36, and survival data. Ten‐year medical activities were used to derive costs. Both unweighted and propensity score‐weighted analyses were performed. Results: The weighted mean of 10‐year QALYs was the highest for radical prostatectomy (8.53), followed by brachytherapy (8.49) and external radiotherapy (8.20), but the difference was only statistically significant with the latter. Costs were significantly higher for brachytherapy (€21,348) than radical prostatectomy (€12,281) and EBRT (€7,560). Compared to EBRT, the weighted ICER for radical prostatectomy was €14,169/QALY gained and €48,417/QALY for brachytherapy. Conclusion: Our findings support that radical prostatectomy was the most cost‐effective alternative, but the differences in effectiveness among the three treatments were small. The incremental cost of radical prostatectomy and brachytherapy compared to EBRT, however, does not justify restricting these alternatives. Trial Registration: ClinicalTrials.gov identifier: NCT01492751